Clinical Trial Update: Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial in men with advanced prostate cancer compares the combination of cediranib and olaparib to olaparib alone, with results posted on 2025-03-30.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer
• Prostate Cancer with Neuroendocrine Differentiation

Drugs mentioned

• Cediranib (Cediranib)
• Lynparza (olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-03-30